STOCK TITAN

I-MAB American Depositary Shares - IMAB STOCK NEWS

Welcome to our dedicated page for I-MAB American Depositary Shares news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-MAB American Depositary Shares stock.

I-Mab American Depositary Shares (Nasdaq: IMAB) represent a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel and highly differentiated biologics to treat diseases with unmet medical needs, focusing on cancers and autoimmune disorders. With operations in Rockville, Maryland, and San Diego, California, I-Mab is actively involved in groundbreaking research and innovative drug development.

The company’s pipeline includes several promising candidates:

  • Felzartamab (TJ202): A CD38 antibody in Phase III trials for multiple myeloma and autoimmune diseases.
  • Eftansomatropin (TJ101): A long-acting human growth hormone that has completed Phase II trials for pediatric growth hormone deficiency.
  • Olamkicept (TJ301): An IL-6 blocker in Phase II trials for ulcerative colitis and autoimmune diseases.
  • Enoblituzumab: A humanized B7-H3 antibody that has completed Phase I trials for head and neck cancer and other oncology diseases.
  • Efineptakin (TJ107): A long-acting recombinant human IL-7 in Phase II trials for glioblastoma multiforme (GBM).

I-Mab's innovative pipeline is driven by its internal R&D strategies, Fast-to-Proof-of-Concept, and Fast-to-Market development, often in collaboration with global partners. Recently, I-Mab announced the divestiture of its Chinese assets and operations, aiming to focus on the U.S. and other international markets. This strategic move included the transfer of its Greater China rights for various assets, potentially generating up to US$80 million based on future milestone achievements.

Notably, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate givastomig combined with nivolumab and chemotherapy as a first-line treatment for advanced Claudin 18.2-positive gastric and esophageal cancers. I-Mab’s robust development pipeline and strategic global partnerships exemplify its commitment to advancing novel therapies to address critical medical needs.

For the latest updates and detailed information, visit the official website at I-Mab Biopharma.

Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a US-based global biotech company focused on developing immunotherapies for cancer treatment, has announced it will release its 1H 2024 financial results on August 28, 2024. The company will host a conference call and webcast at 8:00 AM ET on the same day to discuss financial results, pipeline progress, and recent business highlights for the half year ended June 30, 2024.

Investors and analysts can join the conference call via domestic (1-877-407-0784) or international (1-201-689-8560) dial-in numbers, using the Conference ID: 13747695. A webcast link is also provided. The Call me™ link will be active 15 minutes before the scheduled start time. A replay of the call will be available on the I-Mab website's Investor Relations page for 6 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on cancer immunotherapies, has appointed PricewaterhouseCoopers LLP (PwC US) as its independent registered public accounting firm for fiscal year 2024. This decision, approved by the Audit Committee, is part of I-Mab's strategic transition to become a fully U.S.-based biotech company. The change aims to ensure compliance with the Holding Foreign Companies Accountable Act and aligns with the company's long-term growth objectives.

Interim CEO Sean Fu emphasized that this appointment marks a significant milestone in I-Mab's U.S. transition strategy. CFO Joseph Skelton expressed enthusiasm about working with PwC US, viewing it as beneficial for shareholders. The company assures that this transition was not due to any disagreements or issues with the previous auditor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
management
-
News
Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, has announced significant leadership changes. Mr. Wei Fu has been appointed as the new Chairman of the Board, replacing Dr. Pamela M. Klein. Mr. Raj Kannan is stepping down as CEO and board member, with Dr. Sean Xi-Yong Fu taking over as Interim CEO and joining the board. Dr. Fu brings extensive experience from various biotech roles, including his position as an Operating Partner at ABio-X and former CEO of RVAC Medicines.

The company also announced changes to its Board of Directors and committees, including the resignations of Dr. Ruyi He and Professor Rong Shao. These transitions aim to strengthen I-Mab's leadership as it continues its transformation into a U.S.-based biotech company, focusing on advancing its R&D pipeline and creating value for shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.23%
Tags
management
Rhea-AI Summary

I-Mab (NASDAQ: IMAB) has announced the appointment of Dr. Phillip Dennis as Chief Medical Officer, effective June 17, 2024. Dr. Dennis will lead I-Mab's global clinical development and join the Executive Leadership Team. With two decades of oncology drug development experience, including key roles at Sanofi and AstraZeneca, Dr. Dennis brings significant expertise. His appointment aims to advance I-Mab's clinical pipeline, particularly for treatments like uliledlimab, givastomig, and ragistomig. Before his industry roles, Dr. Dennis was a professor at Johns Hopkins University and a senior investigator at the US National Cancer Institute.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
management
-
Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a global biotech company, has announced a clinical trial collaboration with Bristol Myers Squibb (NYSE: BMY). The focus is on evaluating the combination of givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, with nivolumab and chemotherapy for treating advanced gastric and esophageal cancers. The collaboration leverages promising safety and efficacy data from givastomig's monotherapy study, presented at the European Society of Medical Oncology Congress 2023. The multi-national Phase 1 study will be conducted by I-Mab, with Bristol Myers Squibb supplying nivolumab. The aim is to explore the potential of this combination as a first-line treatment for Claudin 18.2-positive cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
Rhea-AI Summary

I-Mab (NASDAQ: IMAB) announced promising Phase 1 clinical data for its bispecific antibody ragistomig (PD-L1x4-1BB) at the 2024 ASCO Annual Meeting. The data revealed a manageable safety profile and encouraging efficacy in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR). Ragistomig demonstrated an overall response rate (ORR) of 25% at the optimal dose of 5 mg/kg, with a clinical benefit rate (CBR) of 75%. The study included patients with advanced or relapsed/refractory solid tumors, with 71.4% of responders having received prior anti-PD-(L1) therapy. I-Mab highlighted the potential of ragistomig as both monotherapy and in combination with other treatments. The data will be presented by Dr. Gerald Falchook on June 1, 2024, at the ASCO meeting in Chicago.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in immunotherapies for cancer treatment, announced its participation in the Jefferies Global Healthcare Conference on June 5, 2024.

Key presenters include CEO Raj Kannan and Interim CMO Louie Naumovski, with the presentation scheduled for 9:30 a.m. EST. The event will feature one-on-one and small group meetings with key management members, including CFO Joe Skelton and Senior Director of Investor Relations Tyler Ehler.

The presentation will be available via webcast on I-Mab's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

I-Mab, a global biotech company, filed its 2023 annual report on Form 20-F with the SEC. The report focuses on the development of immunotherapies for cancer treatment. It can be accessed on the company's investor relations website and the SEC's website. Shareholders and ADS holders can request hard copies free of charge.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
Rhea-AI Summary
I-Mab (IMAB) to present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024, focusing on immunotherapies for cancer treatment. The presentation will feature key executives and offer opportunities for one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
Rhea-AI Summary
I-Mab successfully closes divestiture transaction transferring equity interest in I-Mab Shanghai, with a total consideration of up to US$80 million. The Company extinguishes repurchase obligations of approximately US$183 million and participates in Series C fundraising of the Hangzhou Company for US$19 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none

FAQ

What is the current stock price of I-MAB American Depositary Shares (IMAB)?

The current stock price of I-MAB American Depositary Shares (IMAB) is $1.02 as of December 6, 2024.

What is the market cap of I-MAB American Depositary Shares (IMAB)?

The market cap of I-MAB American Depositary Shares (IMAB) is approximately 85.6M.

What is I-Mab's core focus?

I-Mab focuses on discovering, developing, and commercializing novel and highly differentiated biologics to treat cancers and autoimmune disorders.

What are some key products in I-Mab's pipeline?

Key products include felzartamab, eftansomatropin, olamkicept, enoblituzumab, and efineptakin.

Where are I-Mab's main operations located?

I-Mab operates primarily from Rockville, Maryland, and San Diego, California.

What recent strategic move has I-Mab made?

I-Mab has divested its Chinese assets and operations to focus more on the U.S. and international markets.

What is felzartamab?

Felzartamab (TJ202) is a CD38 antibody in Phase III trials aimed at treating multiple myeloma and autoimmune diseases.

Who is I-Mab collaborating with on givastomig?

I-Mab is collaborating with Bristol Myers Squibb to study givastomig in combination with nivolumab and chemotherapy for advanced gastric and esophageal cancers.

How does I-Mab fund its operations and research?

I-Mab funds its operations through partnerships, strategic collaborations, and equity investments. Recent strategic divestitures also support its financial health.

What is the significance of the FDA's Breakthrough Therapy designation for felzartamab?

The FDA's Breakthrough Therapy designation for felzartamab recognizes its potential to significantly improve treatment for primary membranous nephropathy and other immune-mediated diseases.

What is I-Mab's approach to drug development?

I-Mab employs Fast-to-Proof-of-Concept and Fast-to-Market strategies, leveraging internal R&D and global partnerships to expedite drug development.

How can investors stay updated on I-Mab's progress?

Investors can stay updated by visiting I-Mab's official website, following their social media channels, and accessing their annual reports and press releases.

I-MAB American Depositary Shares

Nasdaq:IMAB

IMAB Rankings

IMAB Stock Data

85.58M
62.31M
11.16%
30.88%
0.76%
Biotechnology
Healthcare
Link
United States of America
Rockville